Krilov LR - Search Results

1

Respiratory syncytial virus vaccine: where are we now and what comes next?

Noor A, Krilov LR. Noor A, et al. Among authors: krilov lr. Expert Opin Biol Ther. 2018 Dec;18(12):1247-1256. doi: 10.1080/14712598.2018.1544239. Epub 2018 Nov 14. Expert Opin Biol Ther. 2018. PMID: 30426788 Review.

2

Inactivation of respiratory syncytial virus by detergents and disinfectants.

Krilov LR, Harkness SH. Krilov LR, et al. Pediatr Infect Dis J. 1993 Jul;12(7):582-4. doi: 10.1097/00006454-199307000-00007. Pediatr Infect Dis J. 1993. PMID: 8346001

3

Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: potential effect of ribavirin on long term pulmonary function. The Bronchiolitis Study Group.

Krilov LR, Mandel FS, Barone SR, Fagin JC. Krilov LR, et al. Pediatr Infect Dis J. 1997 Mar;16(3):273-6. doi: 10.1097/00006454-199703000-00004. Pediatr Infect Dis J. 1997. PMID: 9076814

4

Epithelial cells infected with respiratory syncytial virus are resistant to the anti-inflammatory effects of hydrocortisone.

Bonville CA, Mehta PA, Krilov LR, Rosenberg HF, Domachowske JB. Bonville CA, et al. Among authors: krilov lr. Cell Immunol. 2001 Nov 1;213(2):134-40. doi: 10.1006/cimm.2001.1869. Cell Immunol. 2001. PMID: 11831875

5

Palivizumab in the prevention of respiratory syncytial virus disease.

Krilov LR. Krilov LR. Expert Opin Biol Ther. 2002 Oct;2(7):763-9. doi: 10.1517/14712598.2.7.763. Expert Opin Biol Ther. 2002. PMID: 12387675 Review.

6

Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States.

Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ. Krilov LR, et al. Value Health. 2010 Jan-Feb;13(1):77-86. doi: 10.1111/j.1524-4733.2009.00586.x. Epub 2009 Aug 24. Value Health. 2010. PMID: 19706010 Free article.

7

Respiratory syncytial virus disease: update on treatment and prevention.

Krilov LR. Krilov LR. Expert Rev Anti Infect Ther. 2011 Jan;9(1):27-32. doi: 10.1586/eri.10.140. Expert Rev Anti Infect Ther. 2011. PMID: 21171875 Review.

8

Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.

Krilov LR, Masaquel AS, Weiner LB, Smith DM, Wade SW, Mahadevia PJ. Krilov LR, et al. BMC Pediatr. 2014 Oct 13;14:261. doi: 10.1186/1471-2431-14-261. BMC Pediatr. 2014. PMID: 25308481 Free PMC article.

9

SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.

Anderson EJ, Krilov LR, DeVincenzo JP, Checchia PA, Halasa N, Simões EA, Domachowske JB, Forbes ML, Pannaraj PS, McBride SJ, McLaurin KK, Kumar VR, Ambrose CS. Anderson EJ, et al. Among authors: krilov lr. Am J Perinatol. 2017 Jan;34(1):51-61. doi: 10.1055/s-0036-1584147. Epub 2016 May 27. Am J Perinatol. 2017. PMID: 27233106 Free article.

10

Enterovirus Infections.

Noor A, Krilov LR. Noor A, et al. Among authors: krilov lr. Pediatr Rev. 2016 Dec;37(12):505-515. doi: 10.1542/pir.2016-0103. Pediatr Rev. 2016. PMID: 27909105 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

131 results

Search Page